Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis.

Patients with multiple myeloma (MM) have increased bone marrow (BM) angiogenesis; however, the proangiogenic properties of myeloma cells and the mechanisms of MM-induced angiogenesis are not completely clarified. The angiopoietin system has been identified as critical in the regulation of vessel formation. In this study we have demonstrated that myeloma cells express several proangiogenic factors, and, in particular, we found that angiopoietin-1 (Ang-1), but not its antagonist Ang-2, was expressed by several human myeloma cell lines (HMCLs) at the mRNA and the protein levels. In a transwell coculture system, we observed that myeloma cells up-regulated the Ang-1 receptor Tie2 in human BM endothelial cells. Moreover, in an experimental model of angiogenesis, the conditioned medium of HMCLs significantly stimulated vessel formation compared with control or vascular endothelial growth factor (VEGF) treatment. The presence of anti-Tie2 blocking antibody completely blunted the proangiogenic effect of XG-6. Finally, our in vitro results were supported by the in vivo finding of Ang-1, but not Ang-2, mRNA and protein expression in purified MM cells obtained from approximately 47% of patients and by high BM angiogenesis in patients with MM positive for Ang-1, suggesting that the angiopoietin system could be involved, at least in part, in MM-induced angiogenesis.

[1]  T. Sonoki,et al.  Expressions of vascular endothelial growth factor and angiopoietin-2 in myeloma cells. , 2003, Haematologica.

[2]  R. Fonseca,et al.  Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  I. Herman,et al.  Mechanisms of normal and tumor-derived angiogenesis. , 2002, American journal of physiology. Cell physiology.

[4]  S. Tian,et al.  Stabilization of breast cancer xenograft tumour neovasculature by angiopoietin-1 , 2002, British Journal of Cancer.

[5]  A. Feller,et al.  Expression of angiopoietin-1 and its receptor TEK in hematopoietic cells from patients with myeloid leukemia. , 2002, Leukemia research.

[6]  H. Namba,et al.  Tie-2 and angiopoietin-1 expression in human thyroid tumors. , 2002, Thyroid : official journal of the American Thyroid Association.

[7]  P. Oettgen,et al.  NERF2, a member of the Ets family of transcription factors, is increased in response to hypoxia and angiopoietin‐1: A potential mechanism for Tie2 regulation during hypoxia , 2002, Journal of cellular biochemistry.

[8]  M. Shikami,et al.  Expression of endothelial cell-associated molecules in AML cells , 2002, Leukemia.

[9]  P. Richardson,et al.  Novel therapies targeting the myeloma cell and its bone marrow microenvironment. , 2001, Seminars in oncology.

[10]  D. Ribatti,et al.  Bone marrow angiogenesis in patients with active multiple myeloma. , 2001, Seminars in oncology.

[11]  N. Munshi,et al.  Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. , 2001, Seminars in oncology.

[12]  W. Bellamy.  Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies. , 2001, Seminars in oncology.

[13]  P. Richardson,et al.  Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications , 2001, Leukemia.

[14]  B. Bussolati,et al.  Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. , 2001, The American journal of pathology.

[15]  L. Ellis,et al.  Differential expression of angiopoietin‐1 and angiopoietin‐2 in colon carcinoma , 2001, Cancer.

[16]  M. Mollenauer,et al.  Endogenous CD28 expressed on myeloma cells up-regulates interleukin-8 production: implications for multiple myeloma progression. , 2001, Blood.

[17]  J. Lim,et al.  Angiopoietin-1 upregulation by vascular endothelial growth factor in human retinal pigment epithelial cells. , 2001, Investigative ophthalmology & visual science.

[18]  S. Kitano,et al.  Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. , 2001, Cancer research.

[19]  S. McLeskey,et al.  Expression and function of angiopoietin-1 in breast cancer , 2000, British Journal of Cancer.

[20]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[21]  Stanley J. Wiegand,et al.  Vascular-specific growth factors and blood vessel formation , 2000, Nature.

[22]  K. Wagner,et al.  Tie2 Receptor Expression Is Stimulated by Hypoxia and Proinflammatory Cytokines in Human Endothelial Cells , 2000, Circulation research.

[23]  P. Rood,et al.  Immortalisation of human bone marrow endothelial cells: characterisation of new cell lines , 2000, European journal of clinical investigation.

[24]  W. Berdel,et al.  Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. , 2000, Blood.

[25]  T. Suda,et al.  In vitro effects of angiopoietins and VEGF on hematopoietic and endothelial cells. , 1999, Biochemical and biophysical research communications.

[26]  G. Yancopoulos,et al.  New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF , 1999, Oncogene.

[27]  Y. Kotake,et al.  Enhanced expression of Tie2, its ligand angiopoietin-1, vascular endothelial growth factor, and CD31 in human non-small cell lung carcinomas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  D. Ribatti,et al.  Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. , 1999, Blood.

[29]  M. Makuuchi,et al.  Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. , 1999, The Journal of clinical investigation.

[30]  G. Yancopoulos,et al.  Critical role of the TIE2 endothelial cell receptor in the development of definitive hematopoiesis. , 1998, Immunity.

[31]  K. Plate,et al.  Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. , 1998, The American journal of pathology.

[32]  Thomas N. Sato,et al.  Increased vascularization in mice overexpressing angiopoietin-1. , 1998, Science.

[33]  K. Pienta,et al.  Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. , 1998, Journal of the National Cancer Institute.

[34]  M. Dewhirst,et al.  Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. , 1997, The Journal of clinical investigation.

[35]  Thomas N. Sato,et al.  Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.

[36]  J. Partanen,et al.  Analysis of Tie receptor tyrosine kinase in haemopoietic progenitor and leukaemia cells , 1997, British journal of haematology.

[37]  A. Waage,et al.  Concomitant Expression of Hepatocyte Growth Factor/Scatter Factor and the Receptor c-MET in Human Myeloma Cell Lines* , 1996, The Journal of Biological Chemistry.

[38]  M. Jourdan,et al.  Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. , 1994, Blood.

[39]  M. Jourdan,et al.  Cytokine gene expression in human multiple myeloma , 1993, British journal of haematology.

[40]  M. Jourdan,et al.  Spontaneous secretion of tumor necrosis factor‐beta by human myeloma cell lines , 1989, Cancer.

[41]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.